证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-034 赛隆药业集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别风险提示 1.赛隆药业集团股份有限公司（以下简称"公司"或"本公司"）股票（证 券简称：*ST 赛隆，证券代码：002898）于 2025 年 6 月 13 日、6 月 16 日、6 月 17 日连续 3 个交易日收盘价格涨幅累计偏离 13.21%，根据深圳证券交易所有关 规定，属于股票交易异常波动的情况。 2.截至本公告披露时，中证指数有限公司的最新数据显示，公司的静态市盈 率为-72.85，市净率为 4.84。公司所属中上协行业分类"C27 医药制造业"的静 态市盈率为 29.11，市净率为 2.85。公司静态市盈率和市净率与同行业的情况有 较大差异，公司特别提醒投资者，注意投资风险，理性决策，审慎投资。 3.近期公司股价短期涨幅较大，明显偏离市场走势，存在市场情绪过热的风 险。但公司基本面没有重大变化，也不存在应披露而未披露的重大信息。公司已 发布多次股票交易异常波动公告及一次股票交易严重异常波动公告， ...

Group 1 - Company GuoDeWei plans to repurchase shares with a total investment of between 100 million to 150 million yuan, with a maximum repurchase price of 53 yuan per share, expecting to buy back between 1.89 million to 2.83 million shares, accounting for 0.78% to 1.17% of total share capital [1] - Company Shuangliang Energy has won a bid for the Gansu Energy Chemical Qinyang 2×660MW coal power project, with a total bid amount of 237 million yuan, representing 1.82% of the company's projected revenue for 2024 [1] - Company China Pacific Insurance reported a total premium income of 227.17 billion yuan from its two subsidiaries in the first five months, with a year-on-year growth of 10.2% for its life insurance subsidiary and 0.5% for its property insurance subsidiary [1][2] Group 2 - Company LuKang Pharmaceutical has received a drug registration certificate for injectable Cefoperazone Sodium, a third-generation cephalosporin with broad-spectrum antibacterial properties [3] - Company 吉祥航空 reported a 4.97% year-on-year increase in passenger turnover in May, with a seat occupancy rate of 86.14%, up 3.70% year-on-year [4][5] - Company DuRui Pharmaceutical's subsidiary has also received a drug registration certificate for injectable Cefoperazone Sodium [6] Group 3 - Company KeLan Software announced that part of the shares held by its controlling shareholder will be auctioned, involving 5.09 million shares, accounting for 1.07% of the total share capital [7] - Company HuaCan Optoelectronics received a government subsidy of 87.84 million yuan, which is expected to positively impact the company's pre-tax profit for 2025 [8] - Company JinZhi Technology has won a bid for projects from the State Grid and China Resources New Energy, with a total bid amount of 84.41 million yuan [9] Group 4 - Company Vision China completed a capital increase for its subsidiary, raising 100 million yuan to accelerate its layout in the AI field [11] - Company Youa Co. received a profit distribution of 96.03 million yuan from its investment in Changsha Bank [13] - Company WanBangde's subsidiary obtained a patent for a deuterated compound, enhancing the chemical stability and reducing toxicity [16] Group 5 - Company DongCheng Pharmaceutical completed the enrollment of all 488 participants in the Phase III clinical trial for Fluorine-18 PSMA peptide injection, aimed at prostate cancer diagnosis [17] - Company China Merchants Expressway announced that its first phase of medium-term notes for 2024 will pay interest on July 2, 2025, with a total issuance of 2.5 billion yuan and an interest rate of 2.35% [18] - Company JinPu Titanium's subsidiary has temporarily suspended production for maintenance due to falling product prices and high production costs [20] Group 6 - Company BeiLu Pharmaceutical received a marketing authorization for Iodinated Contrast Injection in Hungary, marking another approval in the EU [22] - Company LiXing Co. obtained an overseas investment certificate for its wholly-owned subsidiary in Singapore, with a total investment of 2.16 million yuan [24] - Company LangKun Technology won a garbage collection service project with a bid amount of 21.57 million yuan [26] Group 7 - Company KeRui International plans to transfer 55% of its subsidiary Tianjin ZhiRui's equity for 41.96 million yuan [28] - Company Nanjing JuLong intends to invest 130 million yuan to build a production project for special materials with an annual output of 40,000 tons [30] - Company NanShan Intelligent plans to use up to 50 million yuan of idle funds for cash management in safe and liquid financial products [32] Group 8 - Company GuangLian Aviation completed the business change registration for its subsidiary, involving the introduction of strategic investors [34] - Company XiaoFang Pharmaceutical signed a cooperation agreement to develop a new drug for hair loss treatment [36] - Company GuiZhou SanLi plans to sign a 150 million yuan technology transfer and development contract with Guangdong Pharmaceutical University [38] Group 9 - Company ST SiLong's subsidiary received a drug registration certificate for Famotidine injection, used for treating upper gastrointestinal bleeding [52] - Company ZhongKe Information's executive plans to reduce holdings of up to 180,000 shares, accounting for 0.06% of total share capital [53] - Company KeLun Pharmaceutical's injectable Cefoperazone Sodium/Chloride Sodium injection received drug registration approval [54] Group 10 - Company LuXin Investment plans to transfer 10.06% of its stake in LuXin HuiJin for 203 million yuan, aiming to focus on its main business [56] - Company Western Gold plans to acquire 100% of Xinjiang MeiSheng for 1.655 billion yuan [58] - Company JinTou City Development intends to swap assets worth 5.862 billion yuan, changing its main business to urban centralized heating [60]

Policy Developments - The National Health Commission of China is taking measures to ensure blood supply in key areas and important time periods due to a noticeable decline in voluntary blood donations, influenced by factors such as aging population and lifestyle changes [2] - In 2024, the total blood supply in China is expected to decrease year-on-year, with a cumulative blood allocation of 3.613 million units, including 583,000 units allocated between provinces, representing a 35.1% increase [2] Drug and Medical Device Approvals - Kelun Pharmaceutical announced that its subsidiary has received drug registration approval for "Cefazolin Sodium/ Sodium Chloride Injection," which is packaged in a dual-chamber bag and is suitable for emergency treatment [4] - *ST Sailong's subsidiary has obtained a drug registration certificate for Famotidine Injection, classified as a Category A drug under the national medical insurance list, primarily used for treating upper gastrointestinal bleeding [5] Capital Market Activities - Borui Pharmaceutical plans to invest 20 million yuan to subscribe to the increased registered capital of Geek Gene Technology, acquiring a 4.1667% stake in the company [7] Industry Developments - Eli Lilly announced the launch of the multi-dose prefilled pen for Tirzepatide Injection in China, aimed at addressing the needs of the growing number of diabetes and obesity patients [9] - The adult overweight rate in China is 34.3%, with an obesity rate of 16.4%, highlighting the increasing demand for weight management treatments [9] - In the first quarter of this year, Tirzepatide contributed $6.15 billion in revenue to Eli Lilly, accounting for approximately 48% of the company's total revenue [10] - Hanyu Pharmaceutical has completed the enrollment of all subjects for the Phase III clinical trial of Semaglutide Injection for weight management, currently in the follow-up phase [11] Shareholder Actions - Nine Strong Bio's major shareholder completed a share reduction plan, reducing their holdings from 30,969,636 shares to 30,769,636 shares, a decrease from 5.30% to 5.26% of voting shares [13] - Yifeng Pharmacy's controlling shareholder plans to reduce their stake by up to 2%, amounting to no more than 24,248,336 shares [14]

Group 1 - The core point of the article is that *ST Sailong's wholly-owned subsidiary, Hunan Sailong Pharmaceutical (Changsha) Co., Ltd., has received the drug registration certificate for Famotidine injection from the National Medical Products Administration [1] - Famotidine injection is classified as a Class A drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2024) [1] - The drug is primarily indicated for treating upper gastrointestinal bleeding caused by peptic ulcers and other non-tumor related causes of gastric and duodenal mucosal erosion and bleeding, excluding esophageal and gastric variceal bleeding [1]

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-033 赛隆药业集团股份有限公司 关于子公司获得法莫替丁注射液药品注册证书的 公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 规格：1ml：10mg/2ml：20mg 注册分类：化学药品 3 类 证书编号：2025S01758/2025S01757 药品注册标准编号：YBH13102025 药品名称：法莫替丁注射液 剂型：注射剂 赛隆药业集团股份有限公司（以下简称"公司"）全资子公司湖南赛隆药业 （长沙）有限公司于近日获得国家药品监督管理局核准签发的法莫替丁注射液 《药品注册证书》，现将相关情况公告如下： 一、药品基本信息 赛隆药业集团股份有限公司 董事会 药品批准文号有效期：至 2030 年 06 月 09 日 2025 年 6 月 13 日 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明书、 标签及生产工艺照所附执行。本品需在生产线通过 GMP 符合性检查后方可上市。 二、药品其他相关信息 法莫替 ...

Core Viewpoint - *ST Sailong (002898.SZ) has experienced a significant surge in stock price despite poor performance, attributed to plans for a change in control [1][5][6]. Group 1: Stock Performance - Since April 29, *ST Sailong's stock price has skyrocketed from a low of 5.77 yuan to 10.71 yuan, marking a substantial increase [1]. - The stock has hit the daily limit up for six consecutive trading days, reflecting strong market interest [3][6]. Group 2: Ownership Change - On May 20, *ST Sailong announced a share transfer agreement where controlling shareholders Cai Nanguai and Tang Lin plan to transfer 14.16% of their shares to Hainan Yayi [5]. - The share price for this transaction is set at 8 yuan per share, totaling approximately 199 million yuan [5]. - If the transaction proceeds, Hainan Yayi will become the controlling shareholder, and *ST Sailong will transition to having no actual controller [5]. Group 3: Financial Performance - *ST Sailong reported a revenue of approximately 264 million yuan for 2024, a year-on-year decline of 15.15%, with a net profit of -33.14 million yuan, indicating a shift from profit to loss [16]. - The company has faced continuous losses over the past five years, with only one profitable year in 2023 [16][17]. - The first quarter of 2024 showed a revenue of about 54.09 million yuan, down 22.16% year-on-year, with a net profit of -1.04 million yuan [17]. Group 4: New Investor Background - Hainan Yayi, established specifically for this transaction, has a notable partnership structure, including significant players in the biopharmaceutical investment sector [10][11]. - Chen Zhansheng, a key figure in the new investment group, is associated with the well-known Libai Group, indicating potential financial strength and resources for *ST Sailong [19][21].

Group 1 - The core point of the announcement is that the controlling shareholder, Ms. Tang Lin, has completed the procedure for the release of part of her pledged shares in the company [1] - As of the date of the announcement, the pledged shares held by the controlling shareholder and their concerted parties do not pose a risk of forced liquidation and will not significantly impact the company's operations or governance [3] - The company will continue to monitor the status of share pledges and will fulfill its information disclosure obligations in accordance with relevant regulations [3]

赛隆药业集团股份有限公司 证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-032 关于公司控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 赛隆药业集团股份有限公司（以下简称"公司"）于近日接到公司控股股东、 实际控制人唐霖女士的通知，获悉唐霖女士将其持有的本公司部分股份办理了解 除质押手续，具体事项如下： | 股东名 称 | 是否为控股 股东或第一 | 本次解除质 押股份数量 | 占其所持 股份比例 | 占公司总 股本比例 | 起始日 | | 解除日期 | | | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 大股东及其 | （股） | | | | | | | | | | | 一致行动人 | | | | | | | | | | | | | | | | 2025 | 年 | 2025 | | 年 | | | 唐霖 | 是 | 3,000,000 | 31.15% | 1.70% | 03 月 | 07 ...

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别风险提示： 1.赛隆药业集团股份有限公司（以下简称"公司"或"本公司"）股票（证 券简称：*ST 赛隆，证券代码：002898）于 2025 年 5 月 30 日、6 月 3 日、6 月 4 日连续 3 个交易日收盘价格涨幅累计偏离 15.44%，根据深圳证券交易所有关规 定，属于股票交易异常波动的情况。截至 2025 年 6 月 4 日，公司股票交易连续 10 个交易日内 4 次出现同向股票交易异常波动情形，根据深圳证券交易所有关 规定，属于股票交易严重异常波动的情况。 2.截至本公告披露时，中证指数有限公司的最新数据显示，公司的静态市盈 率为-68.98，市净率为 4.59。公司所属中上协行业分类"C27 医药制造业"的静 态市盈率为 29.29，市净率为 2.84。公司静态市盈率和市净率与同行业的情况有 较大差异，公司特别提醒投资者，注意投资风险，理性决策，审慎投资。 3.近期公司股价短期涨幅较大，严重偏离同行业上市公司合理估值和公司基 本面，存在市场情绪过热的风险。但公司基本面没有重大变化，也不存在应 ...

证券代码：002898 证券简称：*ST 赛隆 公告编号：2025-030 赛隆药业集团股份有限公司 关于股票交易异常波动暨风险提示的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 特别风险提示 1.赛隆药业集团股份有限公司（以下简称"公司"或"本公司"）股票（证 券简称：*ST 赛隆，证券代码：002898）于 2025 年 5 月 26 日、5 月 27 日、5 月 28 日连续 3 个交易日收盘价格涨幅累计偏离 16.18%，根据深圳证券交易所有关 规定，属于股票交易异常波动的情况。 2.截至本公告披露时，中证指数有限公司的最新数据显示，公司的静态市盈 率为-62.71，市净率为 4.17。公司所属中上协行业分类"C27 医药制造业"的静 态市盈率为 28.22，市净率为 2.72。公司静态市盈率和市净率与同行业的情况有 较大差异，公司特别提醒投资者，注意投资风险，理性决策，审慎投资。 3.公司于 2025 年 4 月 25 日披露了《2024 年年度报告》，经审计的年度报 告数据显示，公司 2024 年度利润总额、净利润、扣除非经常性损益后的净利 ...